Pfizer Ziprasidone Labeling Stops Short Of Second-Line Use; QT Effect Noted
Executive Summary
Labeling for Pfizer's ziprasidone (Zeldox) recommends that doctors first consider prescribing antipsychotic agents associated with lower rates of QTc prolongation, but stops short of a second-line designation for the drug.
You may also be interested in...
Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market
Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients
Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market
Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients
FDA Working On QT Interval Guidance Under Cardio-Renal’s Throckmorton
FDA Cardio-Renal Drug Products Division Director Douglas Throckmorton, MD, is the chair of an agency working group that is attempting to provide clear advice to industry on how to assess drugs that prolong the QT interval